Knowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey
Open Access
- 31 October 2025
- journal article
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (4) , 512-523
Abstract
Background/Aims: Crohn’s disease (CD) progresses to structural bowel damage (SBD). The Lémann Index (LI) captures stricture extent/severity, penetrating disease and surgery as a SBD score, and is earmarked for future CD modification trials. Understanding knowledge gaps and perceived barriers is critical to wider adoption. Methods: A multinational, cross-sectional study was distributed through a survey link (REDCap, Research Electronic Data Capture) to gastrointestinal professional societies with snowball sampling using 23 questionnaire items in 5 sections to determine SBD and LI knowledge, and LI acceptability. Factors associated with acceptability and perception were evaluated. Results: Of the 107 respondents, 49 (45.8%) were female; 87 (81.3%) were from Europe. Most were inflammatory bowel disease specialists (n = 80, 74.8%) or general gastroenterologists (n = 22, 20.6%), managing > 40 CD patients per month (n = 35, 32.7%). A total of 98 (91.6%) knew about SBD; “very important” rating for clinical trials and clinical practice was 56.1% and 41.4%, respectively. A 39.3% describe LI scoring as “very difficult” or “difficult”; 33.6% reported “significant” or “a lot” of effort. Acceptability (composite scores of > 36) were significantly associated with respondents who had received LI training (P<0.001). Automated methods, intestinal ultrasound and evidence of benefit would encourage LI use in clinical trials, while additional time and automated methods would promote use in clinical practice. The top 3 perceived adoption barriers were: lack of time (60.7%), limited automated methods (47.7%) and need for dedicated radiologists (38.3%). Conclusions: Most respondents had baseline knowledge of SBD. The LI was perceived as important for advancing future CD research and care. More training and automation will facilitate LI adoption.Keywords
Funding Information
- AbbVie
- Portuguese Group of Inflammatory Bowel Disease Studies
This publication has 32 references indexed in Scilit:
- The acceptability of exercise prehabilitation before cancer surgery among patients, family members and health professionals: a mixed methods evaluationSupportive Care in Cancer, 2024
- Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic ReviewJournal of Crohn's and Colitis, 2024
- A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world EvidenceJournal of Crohn's and Colitis, 2022
- A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluationJournal of Gastroenterology, 2022
- Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn’s DiseaseGastroenterology, 2021
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDGastroenterology, 2021
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetAmerican Journal of Gastroenterology, 2015
- Development of the Lémann Index to Assess Digestive Tract Damage in Patients With Crohn's DiseaseGastroenterology, 2015
- The Natural History of Adult Crohn's Disease in Population-Based CohortsAmerican Journal of Gastroenterology, 2010
- A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's diseaseGastroenterology, 2002